Independent Analyst Report on Rapid Nutrition PLC Published by The Zephirin Group
The report offers insights into Rapid Nutrition’s financial outlook, strategy execution, and market opportunities.
London, United Kingdom – 22 September 2025 – Rapid Nutrition PLC (Euronext Growth: ALRPD), an international HealthTech and wellness company, is pleased to advise that The Zephirin Group has released its latest independent equity research report on the Company, dated 18 September 2025.
The report highlights Rapid Nutrition’s recent licensing agreement for Creapure®, regarded as the gold standard in creatine monohydrate, which enhances the Company’s science-led, premium positioning within the performance and wellness market. According to the analysis, this partnership is expected to strengthen Rapid Nutrition’s brand profile, unlock pricing power, and expand its presence across new international markets where Creapure is already well established.
In addition, the report discusses the upcoming launch of the Creapure/SystemLS product, anticipated by late 2025 or early 2026, as a key growth driver supporting the Company’s strategy and reinforcing its premium positioning.
The full report is available to view via the Company’s website.
Please note: This report has been prepared independently by The Zephirin Group and reflects their own opinions. It should not be regarded as a statement or guidance issued by Rapid Nutrition PLC. Access is strictly limited to professional and qualified investors only. Visitors will be required to confirm and accept the applicable terms and conditions before viewing the report.
About Rapid Nutrition
Rapid Nutrition is a global HealthTech company dedicated to advancing wellness through evidence-based, personalized nutrition solutions. Leveraging advanced technologies, AI, and scientific research, the company is committed to optimizing nutrition, improving health outcomes, and fostering sustainable, healthier lifestyles worldwide.
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).